Neurotech launches new YouTube channel to spotlight patients’ stories for rare eye disorder

As Neurotech Pharmaceuticals looks to ramp up the launch of its first-ever commercial product, the biopharma is running a new video series to help boost awareness. The new “Uncovering MacTel” YouTube channel is an educational campaign for people with macular telangiectasia type 2, or MacTel, a vision-robbing neurodegenerative retinal disease. In March 2025, the FDA approved Neurotech’s Encelto for adults with idiopathic MacTel type 2, with the first commercial use coming several months later. MacTel type 2, which primarily occurs in middle-aged adults, can lead to a gradual loss of central vision. The disease affects both eyes, though not always with the same severity. The new YouTube channel launches with 16 short videos that zero in on the experiences of four MacTel patients, including their path to diagnosis and early symptoms. Related The campaign follows a broader trend across pharma of tapping real patients and their stories in a relatively unfiltered and direct way. The bite-sized, to-camera videos help chart the patient pathway, and Neurotech hopes they resonate with people who may be starting their own journey to diagnosis. “Uncovering MacTel was created to help patients better understand their condition through the voices of people who have experienced it firsthand,”
Read More